In vitro activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani Klebsiella pneumonia isolates

Nagina Atlas; Bushra Uzair; Julie Movellan; Raquel Gracia; Damien Dupin; Iraida Loinaz; Cornelus F. van Nostrum; John P. Hays

doi:10.1016/j.heliyon.2023.e22821

In vitro activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani Klebsiella pneumonia isolates

Nagina Atlas
, Bushra Uzair^*
, Julie Movellan
, Raquel Gracia
, Damien Dupin
, Iraida Loinaz
, Cornelus F. van Nostrum
, John P. Hays^*

^*Corresponding author for this work

Medical Microbiology & Infectious Diseases

International Islamic University Islamabad
CIDETEC
Utrecht University

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

43 Downloads (Pure)

Abstract

Klebsiella pneumoniae are bacteria associated with respiratory tract infections and are increasingly becoming resistant to antibiotics, including carbapenems. Apramycin is a veterinary antibiotic that may have the potential to be re-purposed for use in human health, for example, for the treatment of respiratory tract infections after coupling to inhalable nanoparticles. In the present study, the antibiotic apramycin was formulated with single chain polymeric nanoparticles and tested in free and formulated forms against a set of 13 Klebsiella pneumoniae isolates (from the Netherlands and Pakistan) expressing different aminoglycoside resistance phenotypes. Minimum Inhibitory Concentration, Time Kill Kinetics and biofilm experiments were performed providing evidence for the potential efficacy of apramycin and apramycin-based nanomedicines for the treatment of human Klebsiella pneumonia infections.

Original language	English
Article number	e22821
Journal	Heliyon
Volume	9
Issue number	12
DOIs	https://doi.org/10.1016/j.heliyon.2023.e22821
Publication status	Published - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.heliyon.2023.e22821Licence: CC BY

In vitro activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani Klebsiella pneumonia isolatesFinal published version, 2.38 MBLicence: CC BY

Cite this

@article{bc01641cdb0b4bc583152f7330849c21,

title = "In vitro activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani Klebsiella pneumonia isolates",

abstract = "Klebsiella pneumoniae are bacteria associated with respiratory tract infections and are increasingly becoming resistant to antibiotics, including carbapenems. Apramycin is a veterinary antibiotic that may have the potential to be re-purposed for use in human health, for example, for the treatment of respiratory tract infections after coupling to inhalable nanoparticles. In the present study, the antibiotic apramycin was formulated with single chain polymeric nanoparticles and tested in free and formulated forms against a set of 13 Klebsiella pneumoniae isolates (from the Netherlands and Pakistan) expressing different aminoglycoside resistance phenotypes. Minimum Inhibitory Concentration, Time Kill Kinetics and biofilm experiments were performed providing evidence for the potential efficacy of apramycin and apramycin-based nanomedicines for the treatment of human Klebsiella pneumonia infections.",

author = "Nagina Atlas and Bushra Uzair and Julie Movellan and Raquel Gracia and Damien Dupin and Iraida Loinaz and \{van Nostrum\}, \{Cornelus F.\} and Hays, \{John P.\}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = dec,

doi = "10.1016/j.heliyon.2023.e22821",

language = "English",

volume = "9",

journal = "Heliyon",

issn = "2405-8440",

publisher = "Elsevier Ltd.",

number = "12",

}

TY - JOUR

T1 - In vitro activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani Klebsiella pneumonia isolates

AU - Atlas, Nagina

AU - Uzair, Bushra

AU - Movellan, Julie

AU - Gracia, Raquel

AU - Dupin, Damien

AU - Loinaz, Iraida

AU - van Nostrum, Cornelus F.

AU - Hays, John P.

PY - 2023/12

Y1 - 2023/12

N2 - Klebsiella pneumoniae are bacteria associated with respiratory tract infections and are increasingly becoming resistant to antibiotics, including carbapenems. Apramycin is a veterinary antibiotic that may have the potential to be re-purposed for use in human health, for example, for the treatment of respiratory tract infections after coupling to inhalable nanoparticles. In the present study, the antibiotic apramycin was formulated with single chain polymeric nanoparticles and tested in free and formulated forms against a set of 13 Klebsiella pneumoniae isolates (from the Netherlands and Pakistan) expressing different aminoglycoside resistance phenotypes. Minimum Inhibitory Concentration, Time Kill Kinetics and biofilm experiments were performed providing evidence for the potential efficacy of apramycin and apramycin-based nanomedicines for the treatment of human Klebsiella pneumonia infections.

AB - Klebsiella pneumoniae are bacteria associated with respiratory tract infections and are increasingly becoming resistant to antibiotics, including carbapenems. Apramycin is a veterinary antibiotic that may have the potential to be re-purposed for use in human health, for example, for the treatment of respiratory tract infections after coupling to inhalable nanoparticles. In the present study, the antibiotic apramycin was formulated with single chain polymeric nanoparticles and tested in free and formulated forms against a set of 13 Klebsiella pneumoniae isolates (from the Netherlands and Pakistan) expressing different aminoglycoside resistance phenotypes. Minimum Inhibitory Concentration, Time Kill Kinetics and biofilm experiments were performed providing evidence for the potential efficacy of apramycin and apramycin-based nanomedicines for the treatment of human Klebsiella pneumonia infections.

UR - https://www.scopus.com/pages/publications/85178132427

U2 - 10.1016/j.heliyon.2023.e22821

DO - 10.1016/j.heliyon.2023.e22821

M3 - Article

C2 - 38125473

AN - SCOPUS:85178132427

SN - 2405-8440

VL - 9

JO - Heliyon

JF - Heliyon

IS - 12

M1 - e22821

ER -

In vitro activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani Klebsiella pneumonia isolates

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this